FAIRFIELD, Conn., May 13, 2010 (GLOBE NEWSWIRE) -- Competitive Technologies, Inc. (NYSE Amex:CTT) will showcase its Calmare® Pain Therapy Treatment at a symposium for medical professionals in Boston, Mass., on May 17, 2010. Several noted physicians will describe their successful experiences among patients suffering from chronic pain associated with cancer and various types of neuropathic conditions. Medical professionals who wish to attend the conference should contact Kim Thompson at 203.331.4817 or kthompson@competitivetech.net, to ensure adequate space is available on Monday.
The keynote speaker will be Calmare's inventor, Professor Giuseppe Marineo, MD, DSc., Researcher, Founding President of Delta Research and Development, Tor Vergata University of Rome, Italy. Prof. Marineo will present his "Scrambler Therapy," the technology and scientific basis for this revolutionary pain treatment method. Throughout the day, physicians from the Boston Foundation for Sight, the University of Miami, the University of Wisconsin, and Calmar Pain Relief, LLC, will present evidence-based patient case studies developed from their use of this innovative technology to treat various types of chronic pain from cancer and chemotherapy-induced peripheral neuropathy (CIPN), failed back surgery, phantom limb syndrome, as well as pain from shingles, sciatica and a variety of other maladies. Typically, the patients' pain has been resistant to other treatment methodologies, including powerful narcotic painkillers, with associated adverse side effects.
The physicians presenting their evidence-based patient experiences include:
- Perry Rosenthal, MD - Founding President, Vice Chairman and Scientific Director at the Boston Foundation for Sight, and Assistant Clinical Professor of Ophthalmology, Harvard Medical School
- Salahadin Abdi, MD - Professor and Chief, University of Miami Pain Center, Anesthesiology, Perioperative Medicine & Pain Management
- Toby Campbell, MD - Assistant Professor of Medicine, Hematology & Oncology, University of Wisconsin, Paul J. Carbone Cancer Center
- Stephen J. D'Amato, MD, FACEP- Medical Director, Calmar Pain Relief, LLC; Clinical Assistant Professor of Medicine, Boston University School of Medicine, and Medical Staff, Roger Williams Medical Center.
"We are privileged and pleased to have these doctors attest to the effectiveness of our Calmare pain therapy treatment by sharing evidence-based patient successes with other physicians attending our symposium," said John B. Nano, CTT's Chairman, President and CEO. "We are fortunate that on his first U.S visit, Prof. Marineo has taken the time to discuss this innovative technology. I know he will provide a unique perspective for physicians desiring a scientific understanding of the device and its efficacy in relieving patients' pain. Gaining greater knowledge of how the Calmare treatment works will prove very helpful to doctors and other medical professionals."
"With recent media coverage focusing on the negative side effects of morphine and other powerful opioid painkillers, the Calmare therapy offers physicians an effective alternative for treating high intensity oncologic and neuropathic pain, including pain resistant to opioids and other treatment methodologies," Mr. Nano continued. "The Calmare Pain Therapy Treatment, with U.S. FDA clearance and European Union CE Certification for sales, is a prime example of CTT's strategy to connect clinical science to patient care."
For more information about Calmare pain therapy, visit: www.CalmareTT.com. Additional details about the conference can be found at www.competitivetech.net/events/tradeshows.html.
About Competitive Technologies, Inc.
Competitive Technologies, established in 1968, provides distribution, patent and technology transfer, sales and licensing services focused on the needs of its customers and matching those requirements with commercially viable product or technology solutions. CTT is a global leader in identifying, developing and commercializing innovative products and technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT's website: www.competitivetech.net.
Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2009, filed with the SEC on October 27, 2009, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.